<DOC>
	<DOC>NCT01476163</DOC>
	<brief_summary>This program allows physicians to request permission from Amicus Therapeutics (Amicus) for treatment access to migalastat hydrochloride (HCl) for specific adult patients with Fabry disease. Treatment is open label for 6 months with renewal every 6 months.</brief_summary>
	<brief_title>Physician Initiated Expanded Access Request for Migalastat in Individual Patients With Fabry Disease</brief_title>
	<detailed_description>This Physician Initiated Request program allows physicians to request permission from Amicus to receive migalastat HCl for specific patients with Fabry disease who have a mutation amenable to this treatment, who do not have access to available treatment alternatives, or do not meet requirements for participation in an existing migalastat clinical study. Up to 20 patients worldwide may be treated. Patients must meet specific criteria to receive Amicus permission for participation. Key criteria for participation include: 16-74 years old; Confirmed GLA gene mutation shown to be responsive to migalastat; Have no treatment option because either unsuitable for enzyme replacement therapy (ERT) or unable to access ERT. Requirements for sufficient kidney function. If permission is granted, initial approval is for a 6 month supply of migalastat HCl with renewal every 6 months available upon meeting continued eligibility.</detailed_description>
	<mesh_term>Fabry Disease</mesh_term>
	<criteria>Confirmed GLA mutation predicted to be responsive migalastat in the human embryonic kidney (HEK293) cellbased assay 1674 years of age Strong clinical indication for treatment of Fabry disease No other treatment option including either unsuitable for ERT or unable to access ERT Appropriate female and male contraception Willing to receive treatment with migalastat HCl via this program including having signed an authorization for sharing clinical data Estimated glomerular filtration rate (eGFR) or GFR &lt;30 mL/minute Scheduled for renal or other organ transplant or replacement therapy Receiving GLYSET® (miglitol), ZAVESCA® (miglustat) or enzyme replacement therapy FABRAZYME® (agalsidase beta) or REPLAGAL™ (agalsidase alpha) Contraindication to migalastat, i.e., sensitivity to other iminosugar such as miglustat, miglitol Treated with another investigational drug within 30 days of start of migalastat HCl treatment Unable to comply with study requirements or deemed otherwise unsuitable for study entry in the opinion of the investigator.</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>AT1001</keyword>
	<keyword>Lysosomal storage disease</keyword>
	<keyword>Lysosomal Storage Disorder</keyword>
	<keyword>migalastat</keyword>
	<keyword>Fabry disease</keyword>
	<keyword>Fabry</keyword>
	<keyword>Amicus</keyword>
</DOC>